Inhibition of the in vitro infectivity and cytopathic effect of human foamy virus by dideoxynucleosides

AIDS Research and Human Retroviruses

Volumn 12, Issue 15, 1996, Pages 1485-1490

  Santillana Hayat, Maud ^a   Valla, Jocelyne ^a   Canivet, Martine ^a   Peries, Jorge ^a   Molina, Jean Michel ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIDANOSINE; RNA DIRECTED DNA POLYMERASE; VIRUS ANTIGEN; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; ELECTRON MICROSCOPY; GIANT CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; LYMPHOBLASTOID CELL; PRIORITY JOURNAL; RETROVIRUS; SOUTHERN BLOTTING; VIRUS INHIBITION; VIRUS PARTICLE;

EID: 0029827963     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.1485     Document Type: Article

References (26)

1. Mergia A and Luciw PA: Replication and regulation of primate foamy viruses. Virology 1991;184:474-482.
2. Achong BG, Mansell PWA, Epstein MA, and Clifford P: An unusual virus in cultures from a human nasopharyngeal carcinoma. J Natl Cancer Inst 1971;46:299-302.
3. Muller HK, Ball G, Epstein MA, Achong BG, Lenoir G, and Levin A: The prevalence of naturally occurring antibodies to human syncytial virus in East African populations. J Gen Virol 1980; 47:399-406.
4. Schweizer M, Turek R, Hahn H, Schilliephake A, Netzer K, Eder G, Reinhardt M, Rethwilrn A, and Neumann-Haefelin D: Markers of foamy virus infections in monkeys, apes, and accidentally infected humans. Appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retroviruses 1995;11:161-170.
5. Loh PC, Matsuura F, and Mizumoto C: Seroepidemiology of human syncytial virus. Intervirology 1980;13:87-90.
6. Santillana-Hayat M, Rozain F, Bittoun P, Chopin-Robert C, Lasneret J, Peries J, and Canivet M: Transient immunosuppressive effect induced in rabbits and mice by the human spumaretrovirus prototype HFV (human foamy virus). Res Virol 1993;144:389-396.
7. Hooks JJ and Detrick-Hooks B: Simian foamy virus-induced immunosuppression in rabbits. J Gen Virol 1979;44:383-390.
8. Bothe K, Aguzzi A, Lassmann H, Rethwilm A, and Horak I: Progressive encephalopathy and myopathy in transgenic mice expressing human foamy virus genes. Science 1991;253:555-557.
9. Stancek D, Stancekova-Gressnerova M, Janotka M, Hnilica P, and Oravec D: Isolation and some serological and epidemiological data on the viruses covered from patients with subacute thyroiditis de Quervain. Med Microbiol Immunol 1975;161:133-144.
10. Debons-Guillemin MC, Valla J, Gazeau J, et al.: No evidence of spumaretrovirus infection markers in 19 cases of de Quervain's thyroiditis. AIDS Res Hum Retroviruses 1992;8:1547. [Letter]
11. Westarp ME, Kornhuber HH, Roosler J, and Flugel RM: Human spumaretrovirus antibodies in amyotrophic lateral sclerosis. Neurol Psychiatr Brain Res 1992;1:1-4.
12. Lagaye S, Vexiau P, Morozov V, Guenebaut-Claudet V, Tobaly-Tapiero J, Canivet M, Cathelineau G, Peries J, and Emanoil-Ravier R: Human spumaretrovirus-related sequences in the DNA of leucocystes from patients with Graves' disease. Proc Natl Acad Sci USA 1992;89:10070-10074.
13. Schweizer M, Turek R, Reihardt M, and Neumann-Haefelin D: Absence of foamy virus in Graves' disease. AIDS Res Hum Retroviruses 1994;10:601-605.
14. Saib A, Canivet M, Giron ML, Bolgert F, Vala J, Lagaye S, Peries J, and de Thé H: Human foamy virus infection in myasthenia gravis. Lancet 1994;343:666. [Letter]
15. Baltimore D: RNA-dependent DNA polymerase in virions of RNA tumor viruses. Nature (London) 1970;226:1209-1211.
16. Yu SF, Baldwin DN, Gwynn SR, Yendapalli S, and Linial ML: Human foamy virus replication: A pathway distinct from that of retroviruses and hepadnaviruses. Science 1996;271:1579-1582.
17. Mitsuya H and Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type II/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986;83:1911-1915.
18. Matsushita S, Mitsuya H, Reitz MS, and Broder S: Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type 1. J Clin Invest 1987;80:394-400.
19. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennet JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabrai L, Allen S, Kornblau S, Pike MC, and Levine AM: Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alpha and zidovudine. N Engl J Med 1995;332:1744-1748.
20. Connolly KJ and Hammer SM: Antiretroviral therapy: Reverse transcriptase inhibition. Antimicrob Agents Chemother 1992;36: 245-254.
21. Dahlberg JE, Mitsuya H, Broder S, Blam SB, and Aaronson SA: Broad spectrum antiretroviral activity of 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1987;84:2469-2473.
22. Santillana-Hayat M, Tobaly-Tapiero J, Lasneret J, Emanoil-Ravier R, and Peries J: Cell transfection with DNA from simian foamy virus type 1 producing cultures generates equivalent infectious virions. Ann Inst Pasteur 1987;138:369-375.
23. Rhodes-Feuilllette A, Saal F, Lasneret F, Lasneret J, Santilllana-Hayat M, and Peries J: Studies on in vitro interferon sensitivity of simian foamy viruses. Arch Virol 1987;97:77-84.
24. Wybier-Franqui J, Tobaly-Tapiero J, Coronel A, Giron ML, ChopinRobert C, Peries J, and Emanoil-Ravier R: Human foamy virus DNA forms and expression in persistently infected Dami megakaryocytic cells. AIDS Res Hum Retroviruses 1995;11:829-836.
25. Voss G, Nick S, Stahl-Hennig C, Ritter K, and Hunsmann G: Generation of macaque B lymphoblastoid cell lines with simian Epstein-Barr-like viruses: Transformation procedure, characteriation of the cell line, and occurrence of simian foamy virus. J Virol Methods 1992;39:185-195.
26. Westarp ME, Bartmann P, Roosler J, Geiger E, Westphal KP, Schreiber H, Fuchs D, Westarp MP, and Kornhuber HH: Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. Neuroreport 1992;4:819-822.